| Abbreviation | PMCPA |
|---|---|
| Formation | 1 January 1993 |
| Type | Self-regulatory authority |
| Legal status | Division of the Association of the British Pharmaceutical Industry |
| Purpose | Administration of the ABPI Code of Practice for the Pharmaceutical Industry |
| Headquarters | 2nd Floor, Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB, United Kingdom |
Region served | United Kingdom |
Chief Executive | Alex Fell |
| Website | https://www.pmcpa.org.uk/ |
The Prescription Medicines Code of Practice Authority (PMCPA) is a United Kingdom-based self-regulatory body responsible for administering the ABPI Code of Practice for the Pharmaceutical Industry on an independent basis. [1] The PMCPA oversees compliance with the Code, provides guidance and training, and implements the complaints procedure under which promotional materials and activities of pharmaceutical companies are considered. [1]
The PMCPA was established by the ABPI on 1 January 1993 to administer the ABPI Code of Practice at arm's length from the trade association itself. [1] Although the Authority operates independently in its adjudicative role, it remains a division of the ABPI, which is a company limited by guarantee registered in England and Wales. [1]
The primary role of the PMCPA is to administer and enforce the ABPI Code of Practice, which sets ethical standards for the promotion of prescription medicines and interactions between pharmaceutical companies and healthcare professionals and organisations. [1] Its main functions include:
The PMCPA is not an investigatory body in the legal sense; rather, its complaints process is essentially adversarial, with the burden of proof resting on the complainant and evidence provided by both parties to a case. [2]
Complaints alleging breaches of the ABPI Code are submitted to the PMCPA and considered by the Code of Practice Panel. Where appropriate, cases may be referred to the Code of Practice Appeal Board. [2] If a breach is upheld, the PMCPA may impose sanctions including corrective statements, recovery or amendment of promotional materials, audits of company procedures, public reprimands, and other remedies specified under the Code. [1]
Case reports are published by the PMCPA to promote understanding of the Code's application and to provide precedent for future compliance decisions. In some cases, details of findings are also advertised in medical and pharmaceutical press outlets. [1]
In addition to adjudication, the PMCPA offers guidance and training resources to companies and individuals on the requirements of the ABPI Code. This includes on-demand e-learning modules, webinars, and seminars to help stakeholders understand changes to the Code and practical compliance expectations. [1]
Although the PMCPA was established by the ABPI and remains legally a division of that organisation, it is administratively independent and operates at arm's length in the adjudication of Code compliance matters. This independence is intended to ensure impartiality in the interpretation and enforcement of the Code. [1] [3]